Small Cell Lung Cancer (SCLC)

>

Latest News

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.
I-DXd Yields Promising Intracranial Efficacy in ES-SCLC Population

October 19th 2025

Data from IDeate-Lung01 reveal a disease control rate exceeding 90% with infinatamab deruxtecan.

Data from DeLLphi-304 support the use of tarlatamab as a standard of care for all patients with second-line small cell lung cancer.
Tarlatamab Improves Survival vs Chemotherapy in Second-Line SCLC Subgroups

October 18th 2025

Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC

October 18th 2025

Those who had elevated ProGRP at baseline and normalized ProGRP following chemoradiotherapy achieved a median PFS of 49.3 months vs 7.8 months in those who had persistently elevated ProGRP.
Progastrin-Releasing Peptide Levels Correlate With OS and PFS in LS-SCLC

October 4th 2025

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.
Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC

October 3rd 2025

Video Series
Video Interviews
Podcasts
“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.
Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.
In the final part of the small cell lung cancer podcast series, CancerNetwork® and Wade Iams, MD, discuss the future of treating patients with this disease.
In episode 3 of a 4-part small cell lung cancer podcast series, Wade Iams, MD, highlights practical considerations for treating patients with small cell lung cancer, including managing toxicities and the impact of treatment on a patient’s quality of life.
Wade Iams, MD, broke down some of the different treatment options, including lurbinectedin and topotecan, for patients with relapsed/refractory small cell lung cancer in the second episode of a 4-part small cell lung cancer podcast series.
In the first episode of a 4-part series, CancerNetwork® spoke with Wade Iams, MD, about the various first-line treat options that are available for patients with small cell lung cancer.
Latest CME Events & Activities

More News